Sign in Subscribe
Diabetes therapy

Early Initiation of Automated Insulin Delivery Therapy May Improve Glycemic Outcomes in Children and Adolescents with Type 1 Diabetes

Strategic Insights

— 1 min read

A new study published in Diabetes Therapy suggests that early initiation of automated insulin delivery (AID) therapy at the time of diagnosis may be beneficial for children and adolescents with type 1 diabetes (T1D). The study, conducted by researchers at Edge University in Izmir, Turkey, evaluated the impact of initiating MiniMed[TM] 780G at diagnosis on metabolic control and glycemic metrics in newly diagnosed patients with T1D. The findings indicate that early AID initiation may improve glycemic outcomes, including reduced hemoglobin A1c (HbA1c) levels and improved time in range (TIR).

Key Takeaways:

  • Early initiation of AID therapy at the time of diagnosis may improve glycemic outcomes in children and adolescents with T1D.
  • The study found that mean HbA1c levels were significantly lower in the AID group (6.10% or 43 mmol/mol) compared to the continuous glucose monitoring (CGM) + multiple daily injection (MDI) group (7.73% or 61 mmol/mol) at 12 months.
  • Time in range (TIR) was 79.0% in the AID group vs. 50.7% in the CGM + MDI group, and time above range (TAR) was 13.4% vs. 30.7%, respectively.
  • No cases of diabetic ketoacidosis or severe hypoglycemia were reported during the follow-up period.
  • The study highlights the potential benefits of initiating AID therapy at the time of diagnosis, offering novel insights into its safety and efficacy in the early management of T1D.

Statistics:

  • Mean age at diagnosis was 6.98 ± 3.22 years in the AID group and 9.77 ± 4.89 years in the CGM + MDI group (p = 0.14).
  • The AID system was initiated at an average of 3.33 ± 7.73 days (2-23) after diagnosis, while sensor use in the CGM + MDI group began an average of 17.37 ± 8.86 days (1-29) after diagnosis.
  • At 12 months, mean HbA1c levels were 6.10% (43 mmol/mol) in the AID group and 7.73% (61 mmol/mol) in the CGM + MDI group (p = 0.02).
  • TIR was 79.0% in the AID group and 50.7% in the CGM + MDI group (p = 0.02).
  • TAR was 13.4% in the AID group and 30.7% in the CGM + MDI group (p = 0.009).

Sources:

  • Edge University
  • Diabetes Therapy
  • Springer Heidelberg
  • Ugur Cem Yilmaz, Dept. of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Edge University, Izmir, Turkey
  • Gunay Demir, Deniz Ozalp Kizilay, Samim Ozen, and Damla Goksen
  • Springer Heidelberg, Tiergartenstrasse 17, D-69121 Heidelberg, Germany (publisher of Diabetes Therapy)

Read more